{"id": "patient_01_q0", "query": "Which of the following is NOT part of the current treatment regimen for Mrs. Sample's DLBCL?", "options_scores": {"A": 0.054786037653684616, "B": 0.3365107476711273, "C": 0.002086465712636709, "D": 0.32960712909698486, "E": 0.09924603998661041}, "ranked_options": [{"letter": "C", "text": "Cyclophosphamide", "avg_nll": 0.002086465712636709}, {"letter": "A", "text": "Polatuzumab vedotin", "avg_nll": 0.054786037653684616}, {"letter": "E", "text": "Doxorubicin", "avg_nll": 0.09924603998661041}, {"letter": "D", "text": "Vincristine", "avg_nll": 0.32960712909698486}, {"letter": "B", "text": "Rituximab", "avg_nll": 0.3365107476711273}], "correct_answer_letter": "D", "error": null, "method": "local"}
{"id": "patient_01_q1", "query": "In the context of Mrs. Sample's other diagnoses, which of the following is NOT accurate based on the provided information?", "options_scores": {"A": 1.2611942291259766, "B": 0.5065640807151794, "C": 1.147861361503601, "D": 0.634145200252533, "E": 1.6912263631820679}, "ranked_options": [{"letter": "B", "text": "She was diagnosed with primary progressive type of multiple sclerosis.", "avg_nll": 0.5065640807151794}, {"letter": "D", "text": "She has 3-vessel CHD.", "avg_nll": 0.634145200252533}, {"letter": "C", "text": "She has a mood disorder.", "avg_nll": 1.147861361503601}, {"letter": "A", "text": "She has 2-vessel disease", "avg_nll": 1.2611942291259766}, {"letter": "E", "text": "She has pre-existing ALS.", "avg_nll": 1.6912263631820679}], "correct_answer_letter": "D", "error": null, "method": "local"}
{"id": "patient_01_q2", "query": "Which chronic, neuroinflammatory disease does Mrs. Sample suffer from? ", "options_scores": {"A": 0.5790165662765503, "B": 1.1042816638946533, "C": 0.004392143338918686, "D": 3.420034170150757, "E": 0.7412276864051819}, "ranked_options": [{"letter": "C", "text": "Parkinson", "avg_nll": 0.004392143338918686}, {"letter": "A", "text": "Multiple sclerosis", "avg_nll": 0.5790165662765503}, {"letter": "E", "text": "Autoimmune encephalitis", "avg_nll": 0.7412276864051819}, {"letter": "B", "text": "Dementia", "avg_nll": 1.1042816638946533}, {"letter": "D", "text": "Brain abscess", "avg_nll": 3.420034170150757}], "correct_answer_letter": "A", "error": null, "method": "local"}
{"id": "patient_01_q3", "query": "Mrs. Sample takes Fingolimod. What is the dosis and when does the patient take it?", "options_scores": {"A": 1.39181387424469, "B": 1.4855180978775024, "C": 2.0063037872314453, "D": 2.4719038009643555, "E": 2.1087937355041504}, "ranked_options": [{"letter": "A", "text": "0.5 mg, 1 capsule in the morning", "avg_nll": 1.39181387424469}, {"letter": "B", "text": "0.5 mg, 1 capsule at bedtime", "avg_nll": 1.4855180978775024}, {"letter": "C", "text": "50 mg, 1 capsule in the morning", "avg_nll": 2.0063037872314453}, {"letter": "E", "text": "70 mg, 1 capsule in the morning", "avg_nll": 2.1087937355041504}, {"letter": "D", "text": "35 mg, 1 capsule at bedtime", "avg_nll": 2.4719038009643555}], "correct_answer_letter": "B", "error": null, "method": "local"}
{"id": "patient_01_q4", "query": "Which therapy regime does the oncology board recommend for Mrs. Sample?", "options_scores": {"A": 3.8978028297424316, "B": 4.313841819763184, "C": 3.5520355701446533, "D": 0.7787051200866699, "E": 4.5808424949646}, "ranked_options": [{"letter": "D", "text": "6 cycles of R-Pola-CHP", "avg_nll": 0.7787051200866699}, {"letter": "C", "text": "6 cycles of L-Pola-CRP", "avg_nll": 3.5520355701446533}, {"letter": "A", "text": "5 cycles of T-Pola-RHP", "avg_nll": 3.8978028297424316}, {"letter": "B", "text": "7 cycles of R-Luna-CHT", "avg_nll": 4.313841819763184}, {"letter": "E", "text": "8 cycles of M-Pola-CHZ", "avg_nll": 4.5808424949646}], "correct_answer_letter": "D", "error": null, "method": "local"}
{"id": "patient_01_q5", "query": "Mrs. Sample has bone metastasis, of which one was surgically addressed. Where was this metastasis located? ", "options_scores": {"A": 2.146268606185913, "B": 2.1716854572296143, "C": 0.3804052472114563, "D": 1.1209700107574463, "E": 1.5127286911010742}, "ranked_options": [{"letter": "C", "text": "Thoracic vertebra 10", "avg_nll": 0.3804052472114563}, {"letter": "D", "text": "Thoracic vertebra 11", "avg_nll": 1.1209700107574463}, {"letter": "E", "text": "Thoracic vertebra 12", "avg_nll": 1.5127286911010742}, {"letter": "A", "text": "Thoracic vertebra 8", "avg_nll": 2.146268606185913}, {"letter": "B", "text": "Thoracic vertebra 9", "avg_nll": 2.1716854572296143}], "correct_answer_letter": "C", "error": null, "method": "local"}
{"id": "patient_01_q6", "query": "On 01/09/2017, Mrs. Sample received a CT scan of her whole body. What kind of contrast agent was used?", "options_scores": {"A": 0.9986414909362793, "B": 2.432851552963257, "C": 0.7176554203033447, "D": 3.4704771041870117, "E": 2.5743253231048584}, "ranked_options": [{"letter": "C", "text": "Optiray 320", "avg_nll": 0.7176554203033447}, {"letter": "A", "text": "Omnipaque 320", "avg_nll": 0.9986414909362793}, {"letter": "B", "text": "Imeron 400", "avg_nll": 2.432851552963257}, {"letter": "E", "text": "Xenetix 350", "avg_nll": 2.5743253231048584}, {"letter": "D", "text": "Gadovist", "avg_nll": 3.4704771041870117}], "correct_answer_letter": "A", "error": null, "method": "local"}
{"id": "patient_01_q7", "query": "Mrs. Sample received multiple radiologic examinations. In which order did she receive them?", "options_scores": {"A": 2.4081296920776367, "B": 1.445455551147461, "C": 1.9677515029907227, "D": 2.0340042114257812, "E": 2.067744731903076}, "ranked_options": [{"letter": "B", "text": "MR Brain > MR thoracic/lumbar spine > CT chest/abdomen/pelvis > CT Thoracic Spine > CT Thoracic Spine > CT chest/abdomen/pelvis > Abdominal ultrasound > MR Spine > Whole-body PET/CT > Liver MRI", "avg_nll": 1.445455551147461}, {"letter": "C", "text": "MR cervical spine > MR Head > CT Whole Body > CT Thoracic Spine", "avg_nll": 1.9677515029907227}, {"letter": "D", "text": "MR Brain > CT Thoracic Spine > MR cervical spine > CT Whole Body", "avg_nll": 2.0340042114257812}, {"letter": "E", "text": "CT Thoracic Spine > CT Whole Body > MR cervical spine > MR Head", "avg_nll": 2.067744731903076}, {"letter": "A", "text": "MR spine > MR Head > CT Thoracic Spine > CT Whole Body", "avg_nll": 2.4081296920776367}], "correct_answer_letter": "B", "error": null, "method": "local"}
{"id": "patient_01_q8", "query": "Mrs. Sample’ medications changed between admission and discharge. Which of the following statements is correct?", "options_scores": {"A": 0.9747672080993652, "B": 2.844543933868408, "C": 1.012891411781311, "D": 2.5885255336761475, "E": 2.801605463027954}, "ranked_options": [{"letter": "A", "text": "Aspirin was discontinued.", "avg_nll": 0.9747672080993652}, {"letter": "C", "text": "The dose of Sertraline hydrochloride was increased from 50 mg to 100 mg.", "avg_nll": 1.012891411781311}, {"letter": "D", "text": "The patient started taking prednisolone and is recommended to continue taking it for the rest of her life.", "avg_nll": 2.5885255336761475}, {"letter": "E", "text": "The patient started taking 2mg of Melatonin in the evening.", "avg_nll": 2.801605463027954}, {"letter": "B", "text": "The patient started taking Pregabalin 50 mg, 1-0-0-0", "avg_nll": 2.844543933868408}], "correct_answer_letter": "E", "error": null, "method": "local"}
{"id": "patient_01_q9", "query": "Based on the medication changes from admission to discharge, which of the following best describes the Mrs Sample's evolving clinical situation?", "options_scores": {"A": 2.178614377975464, "B": 1.5569744110107422, "C": 2.050903558731079, "D": 1.7558112144470215, "E": 2.044426918029785}, "ranked_options": [{"letter": "B", "text": "The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake.", "avg_nll": 1.5569744110107422}, {"letter": "D", "text": "The patient's mood disorder was deemed stabilized, leading to the discontinuation of Sertraline at discharge.", "avg_nll": 1.7558112144470215}, {"letter": "E", "text": "The patient's immobility concerns were resolved, leading to the discontinuation of Enoxaparin sodium (Clexane®) at discharge.", "avg_nll": 2.044426918029785}, {"letter": "C", "text": "The patient developed a new gastrointestinal issue, hence the introduction of Pantoprazole at discharge.", "avg_nll": 2.050903558731079}, {"letter": "A", "text": "The patient's cardiovascular risk was decreased, leading to a reduced number of cardiovascular medications at discharge.", "avg_nll": 2.178614377975464}], "correct_answer_letter": "B", "error": null, "method": "local"}
